Showing results (1-10 of 28) with videos related to

Sort By:
Pageof 3
Behavioural Brain Research|February 15, 2011
Acute and chronic anxiogenic-like response to fluoxetine in rats in the elevated plus-maze: modulation by stressful handlingGabriel Robert, Dominique Drapier, Danièle Bentué-Ferrer, et al.
Therapie|May 29, 2018
[ISO 9001certification of a quality management system in a clinical investigation center]Jimmy Chesnais, Claire Fougerou-Leurent, Claire Laforest, et al.
BMC Medicine|May 19, 2022
Data-sharing and re-analysis for main studies assessed by the European Medicines Agency-a cross-sectional study on European Public Assessment ReportsMaximilian Siebert, Jeanne Gaba, Alain Renault, et al.
Archives of Internal Medicine|December 15, 2010
Tamsulosin hydrochloride vs placebo for management of distal ureteral stones: a multicentric, randomized, double-blind trialSébastien Vincendeau, Eric Bellissant, Alain Houlgatte, et al.
Leukemia Research|January 21, 2014
Proposal for refining the definition of dysgranulopoiesis in acute myeloid leukemia and myelodysplastic syndromesJean E Goasguen, John M Bennett, Barbara J Bain, et al.
British Journal of Haematology|June 20, 2018
Dyserythropoiesis in the diagnosis of the myelodysplastic syndromes and other myeloid neoplasms: problem areasJean E Goasguen, John M Bennett, Barbara J Bain, et al.
Annals of Intensive Care|May 8, 2016
Design and conduct of the activated protein C and corticosteroids for human septic shock (APROCCHSS) trialDjillali Annane, Christian Brun Buisson, Alain Cariou, et al.
British Journal of Clinical Pharmacology|September 1, 2019
Impact of a targeted monitoring on data-quality and data-management workload of randomized controlled trials: A prospective comparative studyClaire Fougerou-Leurent, Bruno Laviolle, Christelle Tual, et al.
Leukemia Research|April 25, 2016
Quality control initiative on the evaluation of the dysmegakaryopoiesis in myeloid neoplasms: Difficulties in the assessment of dysplasiaJean E Goasguen, John M Bennett, Barbara J Bain, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 3, 2012
Predictive factors of survival after thalidomide therapy in advanced multiple myeloma: long-term follow-up of a prospective multicenter nonrandomized phase II study in 120 patientsOlivier Decaux, Alain Renault, Véronique Sébille, et al.
Pageof 3